This analyst has gotten GILD completely wrong. Hopefully Cramer will discuss this on his show as he is a holder of GILD for his charitable trust. This analyst is a fool. 7-8 years is a long time, with plenty of time for many of GILD's phase 2 and 3 trials to get approved by the FDA. With nearly 4 billion in cash and little to no debt, this stock has $60 written all over it.